XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
   Melanoma
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Skin Channel
subscribe to Skin newsletter

Latest Research : Cancer : Skin

   DISCUSS   |   EMAIL   |   PRINT
Vaccine being researched for prevention of melanoma
Nov 12, 2004, 13:07, Reviewed by: Dr.



 
A recent clinical trial of the NY-ESO1/ISCOMATRIXTM vaccine conducted by the Cancer Vaccine Collaborative group at The Austin Health in Melbourne, Australia, has shown that the vaccine successfully induces a comprehensive immune response and suggests that the vaccine may prevent or delay melanoma recurrence in treated patients.

A team of researchers, including lead authors Ian D. Davis, Weisan Chen, and Jonathan Cebon, published the study in the July 20, 2004, issue of the Proceedings of the National Academy of Sciences of the United States of America. The vaccine, which was composed of the cancer-testis antigen NY-ESO-1 and ISCOMATRIXTM (an adjuvant that enhances the immune system response to the antigen), was administered to cancer patients after surgical removal of their tumors. It was observed that out of the 19 patients who received the vaccine, most with melanoma, 14 were cancer-free two years later.

This phase I clinical trial received much press attention, garnering coverage in several prestigious media outlets including leading Australian newspapers, The Age and the Sydney Morning Herald, the UK’s The London Times, and in the news section of Nature. A larger Phase II clinical trial that will specifically test for the vaccine’s ability to prevent or delay recurrence is now under development.
 

- Cancer Research Institute
 

Free Abstract of the Article (Full Article by Subscription Only):

 
Subscribe to Skin Newsletter
E-mail Address:

 



Related Skin News

Listening to the sound of skin cancer
Malignant melanoma cells secrete a potent embryonic growth factor
Fatty food does not appear to increase the risk of skin cancer
New mouse model technology in Melanoma vaccine tool-box
Malignant melanoma cells reprogrammed !
Gli proteins and tumor latency in skin cancer
New option for patients with metastatic melanoma
Positive family history increases risk of multiple primary melanomas
Skin cancer risk higher in Kidney transplant patients
How some cells repair DNA damage by UV radiation


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us